Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 68,454	$ 293,503
Marketable securities	445,733	0
Prepaid expenses	6,718	5,994
Other current assets	11,825	5,206
Total current assets	532,730	304,703
Property and equipment, net	2,870	245
Indefinite-lived intangible asset	102,500	102,500
Goodwill	6,234	6,234
Other assets	3,997	3,931
Total assets	648,331	417,613
Current liabilities:
Accounts payable	7,989	3,356
Accrued clinical trial expenses	10,621	8,657
Accrued compensation	5,277	6,616
Other accrued expenses	1,845	1,842
Current portion of contingent consideration	32,300	0
Common stock warrant liabilities	343	512
Total current liabilities	58,375	20,983
Contingent consideration	45,900	76,900
Deferred tax liability	17,425	17,425
Other long-term liabilities	3,830	784
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 10,000 shares authorized, none issued and outstanding	0	0
Common stock	42	35
Additional paid-in capital	1,218,710	873,526
Accumulated deficit	(695,954)	(572,040)
Accumulated other comprehensive income	3	0
Total stockholders’ equity	522,801	301,521
Total liabilities and stockholders’ equity	$ 648,331	$ 417,613